US President Donald Trump frequently warns of impending pharmaceutical tariffs, yet the market’s reaction suggests these threats may be overblown. Despite the rhetoric, drugmakers’ stock prices continue to rise, indicating a level of confidence among investors that the tariffs will not materialize or will have minimal impact on the industry.
Source: https://www.barrons.com/articles/lilly-pfizer-jnj-stock-pharma-tariffs-trump-d96e68c1